Pfizer Inc. reported its fourth-quarter and full-year 2024 earnings, surpassing Wall Street expectations. For the fourth quarter, the company achieved adjusted earnings per share of $0.63, beating the consensus estimate of $0.47, and revenue reached $17.76 billion, exceeding the expected $17.26 billion. This performance marked a 22% increase in quarterly revenue from the previous year. Full-year revenue totaled $63.6 billion, up 7% from 2023, with earnings per share at $3.12, above the anticipated $2.97. The company's success was driven by strong sales of its Covid-19 vaccine and pill, as well as cost-cutting measures initiated in the previous year, including downsizing manufacturing and cutting some R&D programs. Pfizer anticipates realizing $4.5 billion in savings by the end of 2025 and an additional $1.5 billion by 2027. Looking ahead, Pfizer reiterated its 2025 outlook, expecting sales between $61 billion and $64 billion, with adjusted earnings per share projected to be between $2.80 and $3.00. The company also faces challenges from Medicare price negotiations and potential impacts from the new Trump administration's policies on vaccines and approvals.